Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Holdings Lifted by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 7.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 795,612 shares of the company’s stock after buying an additional 54,361 shares during the quarter. Nuveen Asset Management LLC owned 1.10% of Kiniksa Pharmaceuticals worth $15,737,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at $355,000. China Universal Asset Management Co. Ltd. increased its stake in Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after purchasing an additional 1,004 shares in the last quarter. Peregrine Capital Management LLC increased its stake in Kiniksa Pharmaceuticals by 1.8% in the 4th quarter. Peregrine Capital Management LLC now owns 244,043 shares of the company’s stock worth $4,827,000 after purchasing an additional 4,361 shares in the last quarter. New York State Common Retirement Fund increased its stake in Kiniksa Pharmaceuticals by 12.4% in the 4th quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock worth $302,000 after purchasing an additional 1,680 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Kiniksa Pharmaceuticals in the 4th quarter worth about $258,000. Institutional investors own 53.95% of the company’s stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, insider Ross Moat sold 23,234 shares of Kiniksa Pharmaceuticals stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $28.02, for a total transaction of $651,016.68. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at $263,808.30. The trade was a 71.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now owns 26,528 shares of the company’s stock, valued at approximately $595,553.60. This represents a 25.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 243,640 shares of company stock valued at $5,986,056 in the last 90 days. 54.57% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals Price Performance

NASDAQ:KNSA opened at $26.89 on Monday. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The stock’s 50-day moving average is $23.26 and its two-hundred day moving average is $21.48. The stock has a market cap of $1.96 billion, a PE ratio of -192.06 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $137.79 million for the quarter, compared to analysts’ expectations of $128.35 million. During the same quarter in the previous year, the business posted ($0.25) EPS. The business’s revenue for the quarter was up 72.5% on a year-over-year basis. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on KNSA. Jefferies Financial Group lifted their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Citigroup began coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.